Streetbeat News

SPRY

ARS Pharmaceuticals, Inc.

Industry

Biotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

ARS Pharmaceuticals' EURneffy adrenaline nasal spray has been approved by the European Commission for emergency treatment of severe allergic reactions, marking the first new delivery method in the EU in over 30 years.

Portfolio Pulse from Benzinga Newsdesk

August 26, 2024 | 1:30 pm

ARS Pharmaceuticals' Neffy, a needle-free nasal spray for allergic reactions, has been FDA approved. It offers convenience over traditional EpiPens but faces skepticism regarding real-world efficacy. Neffy is easier to carry and has a longer shelf life, but concerns about insurance coverage and effectiveness during actual emergencies remain.

Portfolio Pulse from Vandana Singh

August 23, 2024 | 3:43 pm

ARS Pharmaceuticals shares declined after Cantor Fitzgerald initiated coverage with an Overweight rating and set a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 3:40 pm

ARS Pharmaceuticals' Neffy, an epinephrine nasal spray, has been approved by the FDA for emergency allergic reactions. Cantor Fitzgerald initiated coverage with an Overweight rating and a $30 price target, citing Neffy's potential to capture 30% market share and change the allergy treatment paradigm.

Portfolio Pulse from Vandana Singh

August 20, 2024 | 4:21 pm

Fabrinet and several other companies saw significant stock price increases on Tuesday due to strong earnings reports and positive news. Fabrinet's shares rose 18.2% after reporting better-than-expected earnings and issuing strong guidance. Other notable gainers included Bit Digital, NANO Nuclear Energy, Tempus AI, Amer Sports, Hawaiian Holdings, and Palo Alto Networks.

Portfolio Pulse from Avi Kapoor

August 20, 2024 | 2:07 pm

Cantor Fitzgerald has initiated coverage on ARS Pharmaceuticals with an Overweight rating and set a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 9:43 am

ARS Pharmaceuticals (NYSE:SPRY) has seen a 13.47% increase in short interest, with 19.29% of its float sold short. This is higher than its peers' average of 11.82%. The high short interest could indicate bearish sentiment, but it doesn't guarantee a price drop.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 5:30 pm

Loar Holdings Inc. (NYSE:LOAR) reported better-than-expected second-quarter earnings and sales, leading to an 18.2% increase in its stock price. Other notable gainers include iLearningEngines, Inc. (NASDAQ:AILE), Starbucks Corporation (NASDAQ:SBUX), PACS Group, Inc. (NYSE:PACS), Pulse Biosciences, Inc. (NASDAQ:PLSE), and Clean Energy Fuels Corp. (NASDAQ:CLNE), among others.

Portfolio Pulse from Avi Kapoor

August 13, 2024 | 3:44 pm

ARS Pharmaceuticals shares are trading higher after Raymond James upgraded the stock from Outperform to Strong Buy and raised its price target from $18 to $22.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:25 pm

Raymond James analyst Ryan Deschner has upgraded ARS Pharmaceuticals (NASDAQ:SPRY) from Outperform to Strong Buy and raised the price target from $18 to $22.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 9:35 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.